Moderate riskFDA DrugClass II

Brandywine theophylline ER tablets recalled for stability testing gap

Brandywine Pharmaceuticals is recalling one lot of theophylline extended-release tablets, 100 mg, because stability testing for the product was interrupted at a third-party lab. Stability testing checks whether a medicine stays within its quality standards over time. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Check the bottle for NDC 71321-500-10, lot 405617, and expiry 03/31/2028.
  2. Contact your pharmacy or prescriber for a replacement before stopping this medication.
  3. Do not stop taking theophylline suddenly without talking to your doctor, as this can affect your breathing control.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
Sold in
Nationwide
Made for
Adults (under 0 months)

This recall covers 2 products — see all of them.

Details

Units affected
1,620 100-count bottles
Illnesses reported
None reported
Manufactured in
600 W Strasburg Rd, West Chester, Pennsylvania, United States
Classification
Class II
Recall number
D-0110-2027

In the FDA's words

Description
Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10 CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory Lot: 405617, Expiry: 03/31/2028 Distribution: Nationwide within U.S Affected quantity: 1,620 100-count bottles
Hazard
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

2 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

OtherDrugsSold nationwideMore from FDA Drug